Next Article in Journal
Use of Pet in the Management of Non-Small-Cell Lung Cancer in Canada
Previous Article in Journal
Strategies of Sequential Therapies in Unresectable Metastatic Colorectal Cancer: A Meta-Analysis
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
Article

Management of Diarrhea Induced by Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

1
Hematology–Oncology Services, Santa Cabrini Hospital, and Department of Oncology, Faculty of Medicine, McGill University, Montreal, QC
2
Department of Medicine, University of Montreal, Montreal, QC
3
Division of Hematology/Medical Oncology, University of Toronto, Mount Sinai Hospital, and The Princess Margaret Hospital Cancer Centre, Toronto, ON
4
University of Toronto and Medical Oncology/Hematology, Sunnybrook Health Sciences Centre, Toronto, ON
5
University of Toronto, and Division of Gastroenterology, Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, ON
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2014, 21(6), 329-336; https://doi.org/10.3747/co.21.2241
Received: 3 September 2014 / Revised: 7 October 2014 / Accepted: 12 November 2014 / Published: 1 December 2014
Treatment for non-small-cell lung cancer (nsclc) is moving away from traditional chemotherapy toward personalized medicine. The reversible tyrosine kinase inhibitors (tkis) erlotinib and gefitinib were developed to target the epidermal growth factor receptor (egfr). Afatinib, an irreversible ErbB family blocker, was developed to block egfr (ErbB1), human epidermal growth factor receptor 2 (ErbB2), and ErbB4 signalling, and transphosphorylation of ErbB3. All of the foregoing agents are efficacious in treating nsclc, and their adverse event profile is different from that of chemotherapy. Two of the most common adverse events with egfr tkis are rash and diarrhea. Here, we focus on diarrhea. The key to successful management of diarrhea is to treat early and aggressively using patient education, diet, and antidiarrheal medications such as loperamide. We also present strategies for the effective assessment and management of egfr tki–induced diarrhea.
Keywords: non-small-cell lung cancer; epidermal growth factor receptor; tyrosine kinase inhibitors; adverse events; diarrhea management non-small-cell lung cancer; epidermal growth factor receptor; tyrosine kinase inhibitors; adverse events; diarrhea management
MDPI and ACS Style

Hirsh, V.; Blais, N.; Burkes, R.; Verma, S.; Croitoru, K. Management of Diarrhea Induced by Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. Curr. Oncol. 2014, 21, 329-336. https://doi.org/10.3747/co.21.2241

AMA Style

Hirsh V, Blais N, Burkes R, Verma S, Croitoru K. Management of Diarrhea Induced by Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. Current Oncology. 2014; 21(6):329-336. https://doi.org/10.3747/co.21.2241

Chicago/Turabian Style

Hirsh, V., N. Blais, R. Burkes, S. Verma, and K. Croitoru. 2014. "Management of Diarrhea Induced by Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors" Current Oncology 21, no. 6: 329-336. https://doi.org/10.3747/co.21.2241

Find Other Styles

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop